Andreas Tiede: PK-Guided Approaches for Recombinant Porcine Factor VIII in Acquired Hemophilia
Andreas Tiede, Professor in the Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation at Hannover Medical School, shared a post on LinkedIn:
“Dosing of Obizur — recombinant porcine factor VIII — can be challenging due to short half-life in bleeding patients with acquired haemophilia. You can read about our experience with PK-guided continuous infusion and bolus dosing in an upcoming JTH article.”
Read the full article here .
Title: Pharmacokinetic strategies for achieving precise factor VIII control with susoctocog alfa in acquired hemophilia A
Authors: Justus Heeg, Christiane Dobbelstein, Alfonso Iorio, Heiko Schenk, Benjamin Seeliger, Andreas Tiede
Stay updated on the latest scientific advancements with Hemostasis Today.
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC